ClinicalTrials.gg
RecruitingNCT07056049EFODINUpdated Jul 17, 2025

The Efficacy of Additional Motor Training Dosage During the Early Stages Post Stroke on the Upper Extremity Recovery

An interventional study of High dosage, high intensity motor rehabilitation in Stroke and Hemiplegia and Hemiparesis, sponsored by Adi Negev-Nahalat Eran. Recruiting at 2 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Adi Negev-Nahalat Eran · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Stroke with a site in Israel — 12 open to participants now, 21 under way, 3 of them phase 3. Stroke · Israel.

Planned enrollment
51st of 86
50 · median 72
Started
2025
with 3 others
No phase
46 of 127
7 open now
Primary completion
2027-01
later than 10 of 20 live
Registered
121st of 127
by date
Lead sponsor
3 of 127
Adi Negev-Nahalat Eran

Among the 127 studies in Stroke with a site in Israel, this one is the 51st largest by planned enrollment of the 86 interventional ones that give a count, is one of 4 that started in 2025, is one of 46 with no phase, reaches primary completion later than 10 of the 20 other live ones, and was the 121st registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

12 of the 127 studies in Stroke with a site in Israel are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Stroke with a site in Israel, or all of them as a file.
02

Study summary

Intervention abstract

Background: Stroke is the leading cause of long-term disability, and the second leading cause of death in the western world. Most stroke survivors will suffer from motor and cognitive disturbances for the rest of their life, which negatively affects their normal daily life.

Despite the decline in stroke-related mortality over the past decades, the outcome of rehabilitation programs does not improve, and is predictable regardless of the program used. Still, several human and animal studies show that high capacity of training in the early stages post stroke improve motor recovery. This notion is far from being well established.

Aim: Studying the effect of high-dosage, high-intensity training program in the subacute period on upper extremity motor recovery.

Population: Stroke survivors. Study duration: 6 months. Study protocol: Participants will receive additional technology-based upper extremity training for 120 min/day, 5d/w, 4 weeks. They will be monitored pre and post training, and 6 months post-stroke. Outcome measures will include clinical, kinematic and adherence measures (see complete list in the protocol).

03

Conditions studied

  • Stroke
  • Hemiplegia and Hemiparesis

Keywords

  • Stroke Rehabilitation
  • Motor Impairment
  • Post-stroke High Dosage Rehab
  • Technological Rehab Post Stroke
  • Stroke Kinematics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Ischemic or hemorrhagic stroke (hemispheric or brainstem) confirmed by CT or MRI
  • First-ever stroke or previous stroke with no upper extremity weakness
  • 1 week ≤ Time after stroke onset ≤ 6 weeks
  • Active shoulder flexion of at least 20◦ and partial wrist and/or finger active movement
  • Ability to provide inform consent

Exclusion criteria

Exclusion Criteria:

  • A painful shoulder limiting an active forward reach
  • Severe spasticity or non-neural loss of range of motion
  • Cognitive or communication impairments as determined by the clinical team Unstable medical conditions
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    This group will be provided with additional rehab time during the sub actue phase.

    Participants will receive additional technology-based upper extremity training for 120 min/day, 5d/w, 4 weeks. The program will be tailored to their impairment level, and will be added to the usual treatment given during hospitalization.

    Behavioral: High dosage, high intensity motor rehabilitation

  • No intervention
    Matched group from an ongoing project with identical criteria.

    This group is comprised of patients with similar characteristics and the intervention group will be compared to this group.

Interventions

  • BehavioralHigh dosage, high intensity motor rehabilitation

    Participants will receive additional technology-based upper extremity training for 120 min/day, 5d/w, 4 weeks.

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer upper extremity assessment (FM-UE)

    The Upper Extremity Fugl-Meyer Assessment (UE-FMA) is a standardized clinical tool designed to evaluate motor impairment in the upper limb following a stroke. It is part of the broader Fugl-Meyer Assessment, one of the most widely used and validated scales in stroke rehabilitation research. The UE-FMA specifically assesses movement, coordination, and reflexes in the shoulder, elbow, forearm, wrist, and hand, with a maximum score of 66 points. The scale is divided into subcomponents, including upper limb movement (36 points), wrist (10 points), hand (14 points), and coordination/speed (6 points). Each item is scored on a 3-point ordinal scale (0 = cannot perform, 1 = performs partially, 2 = performs fully), offering a total score that reflects the level of motor impairment-higher scores indicate better motor function. The UE-FMA is valued for its reliability, sensitivity to impairment (rather than function), and its ability to track motor recovery over time.

    Time frame: Enrollment, 1 month, 3 months, 6 months after enrollment

  2. Action research arm test (ARAT)

    The Action Research Arm Test (ARAT) is a standardized clinical tool used to assess upper limb function following stroke or neurological injury, with a focus on evaluating the ability to perform purposeful, goal-directed tasks. It consists of 19 items grouped into four subscales: grasp, grip, pinch, and gross movement, each designed to measure different aspects of upper limb activity. Tasks include actions such as picking up small blocks, pouring water, or moving objects across a table. Each item is scored on a 4-point ordinal scale ranging from 0 (no movement) to 3 (normal performance), yielding a maximum total score of 57. The ARAT captures the functional use of the hand and arm in a way that reflects real-world tasks, making it especially relevant for tracking meaningful improvements during rehabilitation. It is known for its high inter-rater and intra-rater reliability and is sensitive to changes in functional performance across a wide spectrum of impairment levels.

    Time frame: Enrollment, 1 month, 3 months, 6 months after enrollment

  3. Stroke Impact Scale (SIS) hand domain, version 2.0

    The Stroke Impact Scale (SIS) hand domain, version 2.0, is a patient-reported outcome measure that assesses the perceived difficulty of using the affected hand in everyday tasks following a stroke. This domain includes five items that ask individuals to rate the difficulty of performing common activities such as carrying heavy objects, turning a doorknob, or picking up a coin. Each item is scored on a 5-point Likert scale ranging from 1 (could not do it at all) to 5 (not difficult at all), reflecting the patient's experience over the past week. Scores are converted to a 0-100 scale, with higher scores indicating better perceived hand function. The SIS hand domain captures the individual's perspective on the functional impact of stroke on daily activities, providing valuable insight into real-world hand use. It is frequently used in stroke rehabilitation studies to complement performance-based assessments and to evaluate patient-centered outcomes.

    Time frame: Enrollment, 1 month, 3 months, 6 months after enrollment

  4. Kinematics

    Using reaching tasks that will be recorded using multiple high resolution video-cameras and analyzed using AI algorithm (OpenPose). Outcome measures that will be examined include: trajectory smoothness, reaching extent, shoulder-elbow synergy, movement time and deviation from trajectories of age matched healthy controls.

    Time frame: Enrollment, 1 month, 3 months, 6 months

Secondary outcomes

  1. Upper extremity activity

    Daily natural activity will be monitored for using IMUs (Movella DOT) worn on upper extremity and trunk for periods of up-to 6 hours.

    Time frame: Enrollment and 3 months.

  2. Time on task

    Actual time spent training during a practice session.

    Time frame: The measure will be recorded every single practice session, twice a day, 5 days a week. Total Time on Task will be calculated at the end of the intervention period, approximately 4 weeks.

  3. Attendance

    The rate in which a participant actively participated in the training sessions.

    Time frame: The measure will be recorded every single practice session, twice a day, 5 days a week. Total attendance will be calculated at the end of the intervention period, approximately after 4 weeks.

  4. Visual Analogue Scale for pain

    The VAS is a self-report measure consisting of a 10 centimeter line with a statement at each end representing one extreme of pain intensity (No pain and pain as bad as it could possibly be). The participant gives their indication with a pen mark on the line corresponding to their present pain level. The higher the score, the worse the pain.

    Time frame: The measure will be recorded before and after every single practice session, twice a day, 5 days a week. The mean pain level delta will be calculated at the end of the intervention period, approximately 4 weeks.

  5. Rating of perceived exertion (RPE)

    The revised category-ratio scale (0 to 10 scale) will be used to monitor and guide exercise intensity. Participants subjectively rate their level of exertion during exercise (American College of Sports Medicine, 2010). A higher score means higher exertion experienced by the participant during the session. It is not necessarily good or bad, it is just an indication of the effort.

    Time frame: The measure will be recorded every single practice session, twice a day, 5 days a week.

  6. The Intrinsic Motivation Inventory (IMI)

    The IMI is a validated self-report tool used to assess intrinsic motivation toward a specific activity. It includes multiple subscales, with Interest/Enjoyment considered the primary indicator of intrinsic motivation. Items are rated on a 7-point Likert scale (1 = not at all true, 7 = very true), and subscale scores are averaged to produce interpretable values. Higher scores reflect greater intrinsic motivation, perceived competence, or effort, depending on the subscale.

    Time frame: At the end of the intervention period for each participant (i.e. 4 weeks).

Other outcomes

  1. Berg Balance Scale (BBS)

    Consists of 14 items for assessing static and dynamic balance and risk of falls for different populations. The test includes different tasks in various challenging positions and scored up to 56 points. A higher score indicated better balance and lower risk of falls.

    Time frame: Only at enrollment.

  2. Fatigue Severity Scale (FSS)

    The 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders. A higher scale indicated higher fatigue level.

    Time frame: At the end of the intervention period (i.e. 4 weeks)

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Miller EL, Murray L, Richards L, Zorowitz RD, Bakas T, Clark P, Billinger SA; American Heart Association Council on Cardiovascular Nursing and the Stroke Council. Comprehensive overview of nursing and interdisciplinary rehabilitation care of the stroke patient: a scientific statement from the American Heart Association. Stroke. 2010 Oct;41(10):2402-48. doi: 10.1161/STR.0b013e3181e7512b. Epub 2010 Sep 2. No abstract available. PubMed 20813995 ↗
  • Kwakkel G, Kollen BJ, van der Grond J, Prevo AJ. Probability of regaining dexterity in the flaccid upper limb: impact of severity of paresis and time since onset in acute stroke. Stroke. 2003 Sep;34(9):2181-6. doi: 10.1161/01.STR.0000087172.16305.CD. Epub 2003 Aug 7. PubMed 12907818 ↗
  • Buch ER, Rizk S, Nicolo P, Cohen LG, Schnider A, Guggisberg AG. Predicting motor improvement after stroke with clinical assessment and diffusion tensor imaging. Neurology. 2016 May 17;86(20):1924-5. doi: 10.1212/WNL.0000000000002675. Epub 2016 Apr 29. No abstract available. PubMed 27164664 ↗
  • Biernaskie J, Chernenko G, Corbett D. Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. J Neurosci. 2004 Feb 4;24(5):1245-54. doi: 10.1523/JNEUROSCI.3834-03.2004. PubMed 14762143 ↗

Individual participant data

Plan to share: Yes — The individual participant data to be shared will include de-identified information collected during the trial, such as demographic and baseline characteristics, intervention allocations, and all outcome measures used in both the primary and secondary analyses. In addition, supporting documentation will be provided to facilitate proper use of the data, including the study protocol, statistical analysis plan, informed consent form template, and a comprehensive data dictionary.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: The de-identified individual participant data and supporting documentation will be made available beginning six months after publication of the primary results and will remain accessible for a minimum of five years thereafter.

Access criteria: Qualified researchers with a scientifically sound proposal will be able to request access to the de-identified individual participant data and supporting documents, including the study protocol, statistical analysis plan, informed consent form template, and data dictionary. Access will be granted through a secure data repository following submission and approval of a data access request. Researchers will be required to sign a data use agreement outlining conditions for responsible data use, including maintaining confidentiality and using the data only for the approved purpose. Access will be provided through controlled mechanisms, such as registered user accounts or institutional credentials, depending on the repository's access procedures.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 18 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jul 9, 2025
StartActual
Jul 13, 2025
Primary completionEst.
Jan 15, 2027
CompletionEst.
Jul 15, 2027
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07056049
Lead sponsor
Adi Negev-Nahalat Eran
Collaborators
Ben-Gurion University of the Negev
Responsible party
Sponsor
First posted
Jul 9, 2025
Start date
Jul 13, 2025
Primary completion
Jan 15, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Jul 17, 2025

Study contacts

Gil Meir
Contact
gilmeir10@gmail.com
+972 0548340307
Lior Shmuelof, Prof.
principal investigator · Ben-Gurion University of the Negev

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion